ERR-α Ligand Dissociation Rate Measurement via Crystallization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack effective means to modulate Estrogen Related Receptor alpha (ERR-α) activity for treating various diseases, including bone-related disorders and breast cancer, due to limited understanding of ERR-α ligands and their binding mechanisms.
Innovation Solution
A crystallized form of ERR-α in complex with a ligand forming a thioether bond to Cys325 is used to determine the three-dimensional structure, allowing for the design of ligands that can modulate ERR-α activity through specific amino acid interactions and measurement of dissociation rates.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional methods are used to study ERR-α ligands, then general binding information can be obtained, but specific binding mechanisms and dissociation rates cannot be measured
Solution Approach 1:
The patent uses crystallized ERR-α protein as an intermediary system to enable measurement of dissociation rates. The crystal structure provides a stable platform that allows precise measurement of ligand binding and dissociation events that cannot be measured in solution, thus resolving the contradiction between measurement precision and system complexity.
Solution Approach 2:
The patent changes the physical state of the ERR-α ligand complex from solution phase to crystalline phase. This parameter change enables the measurement of dissociation rates with high precision, as the crystal lattice provides a controlled environment that stabilizes the complex and allows precise kinetic measurements.
2Stability of the object's composition
If ligands form reversible covalent bonds with ERR-α, then stable binding is achieved, but measurement of dissociation becomes difficult
Solution Approach 1:
The patent performs preliminary crystallization of the ERR-α ligand complex before attempting to measure dissociation rates. This preliminary action stabilizes the reversible covalent bond in a defined structural context, allowing subsequent measurement of dissociation events that would otherwise be too rapid or unstable to measure accurately.
Solution Approach 2:
The patent creates multiple identical copies of the ERR-α ligand complex in the crystal lattice. This allows statistical measurement of dissociation events across many identical complexes, improving the precision of dissociation rate measurements for stable reversible covalent bonds through ensemble averaging.
3Loss of information
If crystal structure determination is performed, then detailed binding mechanisms can be understood, but time and resource consumption increase
Solution Approach 1:
The patent segments the research process into distinct phases: crystallization, structure determination, and dissociation rate measurement. Each phase provides specific information (structural details, binding mechanisms, kinetic parameters) that together comprehensively characterize the ligand-protein interaction, reducing the need for prolonged single-method studies.
Solution Approach 2:
The patent maintains continuous useful action by using the same crystallized samples for both structure determination and dissociation rate measurements. This eliminates the need to prepare separate samples for different types of measurements, reducing time loss while maintaining information continuity about the binding mechanism.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables the rational design of ligands that can effectively modulate ERR-α activity, providing therapeutic options for diseases mediated by ERR-α, such as bone-related disorders and breast cancer, by identifying attachment sites and optimizing ligand binding.
Implementation Method 1
a ligand that forms a thioether bond to Cys325 of ERR-α
Implementation Method 2
X-ray diffraction analysis, three-dimensional structural determination
Implementation Method 3
X-ray diffraction data for a complex of ERR-α and the ligand
Data Source
AI summary
The crystal structure of the ligand binding domain of ERR-α in complex with a ligand that forms a reversible thioether bond to Cys325 of ERR-α, methods to measure dissociation rates for ligands that form reversible covalent bonds, and methods to design ligands that form reversible covalent bonds for use as modulators of ERR-α activity are disclosed. The crystal structure and methods provide a novel molecular mechanism for modulation of the activity of ERR-α and provide the basis for rational drug design to obtain potent specific ligands for use as modulators of the activity of this new drug target.